Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL
暂无分享,去创建一个
Ryan D. Morin | L. Rimsza | Y. Asmann | R. Morin | S. Slager | V. Sarangi | S. Ansell | N. Stong | M. Maurer | A. Novak | S. Khan | P. Mondello | R. King | R. Mwangi | A. Gandhi | A. Feldman | J. Cerhan | T. Habermann | K. Wenzl | J. Krull | B. Link | J. Walker | G. Nowakowski | M. Ortiz | M. Stokes | M. Hopper | A. Dropik | J. Novak | A. Bock | C. Huang | G. Nowakowski
[1] M. Kersten,et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma , 2021, New England Journal of Medicine.
[2] Shouying Xu,et al. The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression? , 2021, Frontiers in Oncology.
[3] Aaron M. Newman,et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. , 2021, Cancer cell.
[4] J. Sicklick,et al. Targeting ARID1A mutations in cancer. , 2021, Cancer treatment reviews.
[5] J. Leonard,et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. , 2021, Cancer discovery.
[6] J. Cerhan,et al. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients , 2020, Blood Cancer Journal.
[7] Ryan D. Morin,et al. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. , 2020, Blood advances.
[8] Ryan D. Morin,et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.
[9] S. Barrans,et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. , 2020, Blood.
[10] J. Cerhan,et al. Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL , 2020, Leukemia.
[11] J. Cerhan,et al. Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. , 2020, Blood.
[12] L. Sehn,et al. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. , 2019, Haematologica.
[13] C. Copie-Bergman,et al. Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles , 2019, EBioMedicine.
[14] J. Cerhan,et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma , 2019, Blood Cancer Journal.
[15] Ryan D. Morin,et al. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Barrans,et al. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Dharmesh D. Bhuva,et al. Single sample scoring of molecular phenotypes , 2018, BMC Bioinformatics.
[18] Steven J. M. Jones,et al. Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma , 2018, Nature Communications.
[19] G. Mills,et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade , 2018, Nature Medicine.
[20] Stefano Monti,et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.
[21] Roland Schmitz,et al. Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.
[22] Steven J. M. Jones,et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.
[23] A. Tzankov,et al. High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations , 2018, Leukemia.
[24] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[25] J. Cerhan,et al. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. , 2017, International journal of epidemiology.
[26] D. Dunson,et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.
[27] A. Rosenwald,et al. TP53 mutation and survival in aggressive B cell lymphoma , 2017, International journal of cancer.
[28] J. Cerhan,et al. Personalized risk prediction for event‐free survival at 24 months in patients with diffuse large B‐cell lymphoma , 2016, American journal of hematology.
[29] W. A. Mardin,et al. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma , 2015, PloS one.
[30] Chih-Yi Chen,et al. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2 , 2015, Oncotarget.
[31] Wei Zhang,et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. , 2015, Cancer discovery.
[32] Benjamin G. Bitler,et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.
[33] R. Gascoyne,et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] T. Nagase,et al. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability. , 2014, Cancer research.
[35] J. Cerhan,et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Noske,et al. ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas , 2013, International journal of molecular sciences.
[37] W. Choi,et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.
[38] Michael R. Green,et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. , 2012, Cancer cell.
[39] I. Shih,et al. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. , 2012, Neoplasia.
[40] H. Tsuda,et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations , 2012, Modern Pathology.
[41] Eric S. Lander,et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.
[42] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[44] D. Rossi,et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.
[45] S. Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[46] A. Rosenwald,et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. , 2008, Blood.
[47] T. Golub,et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.
[48] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[49] B. Gusterson,et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.
[50] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[51] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.
[52] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[53] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[54] Sonali M. Smith,et al. Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.